Healthcare provider profile · identity verified

Ramon R Pineyro, MD

General Practice · CAROLINA, PR · NPI 1558330993

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	392	113
Pantoprazole Sodium	Pantoprazole Sodium	232	46
Levothyroxine Sodium	Levothyroxine Sodium	227	45
Amlodipine Besylate	Amlodipine Besylate	200	47
Simvastatin	Simvastatin	197	43
Lisinopril	Lisinopril	181	48
Gabapentin	Gabapentin	180	38
Alendronate Sodium	Alendronate Sodium	172	38
Glimepiride	Glimepiride	141	27
Metoprolol Succinate	Metoprolol Succinate	138	47
Meclizine Hcl	Meclizine Hcl	126	32
Famotidine	Famotidine	120	34
Losartan Potassium	Losartan Potassium	117	34
Clonazepam	Clonazepam	114	25
Metformin Hcl Er	Metformin Hcl	111	27
Omeprazole	Omeprazole	110	25
Metformin Hcl	Metformin Hcl	105	23
Enalapril Maleate	Enalapril Maleate	102	19
Lantus	Insulin Glargine,hum.Rec.Anlog	96	14
Synthroid	Levothyroxine Sodium	88	22
Carvedilol	Carvedilol	81	20
Hydrochlorothiazide	Hydrochlorothiazide	79	23
Repaglinide	Repaglinide	78	14
Rosuvastatin Calcium	Rosuvastatin Calcium	76	22
Tizanidine Hcl	Tizanidine Hcl	74	38
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	73	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	67	17
Candesartan Cilexetil	Candesartan Cilexetil	63	18
Ibandronate Sodium	Ibandronate Sodium	62	24
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	58	13
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	56	16
Clopidogrel	Clopidogrel Bisulfate	56	18
Albuterol Sulfate Hfa	Albuterol Sulfate	55	12
Atenolol	Atenolol	55	suppressed
Lorazepam	Lorazepam	54	suppressed
Sure Comfort	Syringe-Needle,insulin,0.5 Ml	50	suppressed
Alprazolam	Alprazolam	46	suppressed
Azithromycin	Azithromycin	46	38
Latanoprost	Latanoprost	43	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	43	12
Diclofenac Potassium	Diclofenac Potassium	41	24
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	40	12
Nifedipine Er	Nifedipine	40	14
Montelukast Sodium	Montelukast Sodium	38	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	suppressed
Diclofenac Sodium	Diclofenac Sodium	35	20
Januvia	Sitagliptin Phosphate	34	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	33	suppressed
Irbesartan	Irbesartan	33	suppressed
Pentoxifylline	Pentoxifylline	33	suppressed
Sertraline Hcl	Sertraline Hcl	33	suppressed
Tramadol Hcl	Tramadol Hcl	32	suppressed
Farxiga	Dapagliflozin Propanediol	30	suppressed
Fenofibrate	Fenofibrate	30	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	29	suppressed
Ramipril	Ramipril	29	suppressed
Tradjenta	Linagliptin	29	suppressed
Folic Acid	Folic Acid	28	suppressed
Nabumetone	Nabumetone	28	suppressed
Dexamethasone	Dexamethasone	27	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	suppressed
Lumigan	Bimatoprost	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	suppressed
Cefadroxil	Cefadroxil	23	17
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	23	16
Glipizide	Glipizide	22	suppressed
Hydrocortisone	Hydrocortisone	22	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	20
Eliquis	Apixaban	21	suppressed
Paroxetine Er	Paroxetine Hcl	21	suppressed
Humalog	Insulin Lispro	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	20	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	18	suppressed
Mometasone Furoate	Mometasone Furoate	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Tadalafil	Tadalafil	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	15	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Albuterol Sulfate	Albuterol Sulfate	14	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Allopurinol	Allopurinol	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Mupirocin	Mupirocin	13	11
Pen Needle	Pen Needle, Diabetic	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Furosemide	Furosemide	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Trazodone Hcl	Trazodone Hcl	12	suppressed
Valsartan	Valsartan	12	suppressed
Ammonium Lactate	Ammonium Lactate	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Humulin N	Insulin Nph Human Isophane	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Temazepam	Temazepam	11	suppressed
Xarelto	Rivaroxaban	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error